Insights
Search Results
Client Highlights
9.12.25
Wilson Sonsini Advises Avidity Biosciences on Patent Matters Related to $600 Million Upsized Public Offering
On September 12, 2025, Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), announced the pricing of its upsized underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $40.00 per share. All of the shares to be sold in the offering are to be sold by Avidity. The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $600 million. Wilson Sonsini Goodrich & Rosati is advising Avidity Biosciences on patent matters related to the transaction.
Client Highlights
10.10.24
Wilson Sonsini Advises on Patent Matters Related to Verona’s FDA Approval
On June 26, 2024, Verona Pharma announced that the U.S. Food and Drug Administration approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvayre is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years. Wilson Sonsini Goodrich & Rosati advised Verona Pharma on patent matters.
Client Highlights
8.19.24
Firm Advises Avidity Biosciences on IP Matters Related to Public Offering
On August 19, 2024, Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), announced that it has closed its previously announced underwritten public offering of 8,418,000 shares of its common stock, including 1,098,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $41.00 per share. The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $345.1 million. Wilson Sonsini Goodrich & Rosati is patent counsel to Avidity and represented the company in IP matters related to this transaction.
Client Highlights
6.18.24
Wilson Sonsini Advises Avidity Biosciences on Patent Matters Related to $461 Million Public Offering
On June 17, 2024, Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), announced that it had closed an underwritten public offering of 12,132,500 shares of its common stock, including 1,582,500 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $38.00 per share. The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $461.0 million. Wilson Sonsini Goodrich & Rosati advised Avidity on patent matters related to the transaction.
Client Highlights
5.16.24
Wilson Sonsini Advises Venrock on IP Matters Related to Lycia Therapeutics’ $106 Million Series C
On May 13, 2024, Lycia Therapeutics, Inc., a leader in extracellular protein degradation, announced the completion of an oversubscribed $106.6 million Series C financing. Venrock Healthcare Capital Partners led the round, with participation from new investors Janus Henderson Investors, Marshall Wace, and Franklin Templeton, and existing investors Redmile Group, RTW Investments, Blue Owl Healthcare Opportunities (formerly Cowen Healthcare Investments), Invus, Eli Lilly and Company, and Alexandria Venture Investments.
Client Highlights
3.21.24
Wilson Sonsini Advises LENZ Therapeutics on Completed Merger with Graphite Bio
On March 21, 2024, LENZ Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, announced the completion of its previously announced merger with Graphite Bio, Inc. The new combined company will operate under the name LENZ Therapeutics, Inc. and will commence trading on Nasdaq under the ticker symbol “LENZ” on March 22, 2024. Wilson Sonsini Goodrich & Rosati advised LENZ Therapeutics on the transaction.
Client Highlights
3.01.24
Wilson Sonsini Advises vTv Therapeutics on Patent Matters Related to $51 Million Private Placement Financing
On February 28, 2024, vTv Therapeutics, a clinical-stage biopharmaceutical company, announced that it successfully closed a private placement financing (PIPE) to healthcare-focused institutional investors. Total gross proceeds of the PIPE were $51 million. Wilson Sonsini Goodrich & Rosati advised vTv Therapeutics on patent matters related to the transaction.
Client Highlights
2.29.24
Firm Advises Avidity Biosciences on Patent Matters Related to $400 Million Private Placement
On February 29, 2024, Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), announced that it has agreed to sell 15,224,773 shares of its common stock at a price of $16.50 per share and pre-funded warrants to purchase 9,030,851 shares of its common stock at a price per pre-funded warrant of $16.4990 to a select group of institutional and accredited healthcare specialist investors in an oversubscribed private placement. Wilson Sonsini Goodrich & Rosati advised Avidity on patent matters related to the transaction.
Client Highlights
11.15.23
Wilson Sonsini Represents LENZ Therapeutics in Merger with Graphite Bio
On November 15, 2023, LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The lead programs of the combined company will address presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over the age of 45. The combined company is expected to trade on Nasdaq under the ticker symbol “LENZ.” Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction.